We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Funding whizzy

8 September 2004 By Robert Cyran

The UK government has appointed Paul Myners, the chair of M&S, to examine relaxing preemption rights for biotech companies. Creating different capital raising rules for favoured sectors sets a bad precedent.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)